We read with great interest the article in CHEST (June 2015) by Hautefort et al, 1 who demonstrated activity of the T helper 17 pathway in patients with idiopathic pulmonary arterial hypertension (IPAH). Th e authors further substantiated a potential role of an autoimmune pathogenesis in IPAH, a disease defi ned by the absence of known causes or associated conditions. "A fl avor of autoimmunity" in IPAH, as discussed by the authors, 1 also arises from studies showing a high prevalence of auto-antibodies in patients with IPAH and their role in in vitro models. 1 , 2 IL-17A can be detected in the circulation of patients with cardiovascular diseases. However, in that population, concerns regarding the pathogenic infl uence of IL-17A are raised by Simon et al, 3 who showed, albeit inconsistently with the assumed deleterious role for IL-17A in atherosclerosis, a favorable outcome for patients with acute myocardial infarction and high levels of circulating IL-17A. 4 We hypothesized that circulating IL-17A levels are also altered in a subset of patients with IPAH. Th irty-two patients with IPAH, diagnosed according to current recommendations, 5 and seven age-and Data are presented as mean Ϯ SD unless otherwise indicated. 6MWD 5 6-min walking distance; ERA 5 endothelin-receptor antagonist; mPAP 5 mean pulmonary arterial pressure; NT-proBNP 5 N-terminal prohormone of brain natriuretic peptide; PDE5-I 5 phosphodiesterase-5 inhibitor; PVR 5 pulmonary vascular resistance; RAP 5 right atrial pressure; RVSP 5 right ventricular systolic pressure; 
sex-matched healthy subjects were prospectively recruited between 2011 and 2012 at the University Medical Center Hamburg-Eppendorf, Germany. Six-minute walking distances (6MWDs), World Health Organization functional class, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) level, and echocardiographic assessment were obtained on the day of sample collection. Serum samples were stored at 2 80°C and thawed only for measurement of IL-17A concentration using an enzyme-linked immunosorbent assay with a sensitivity threshold of 2 ng/L (Biosource Europe SA).
Elevated levels of IL-17A ( . 2 ng/L) were found in fi ve of 32 patients with IPAH (16%), with a mean level of 7.44 Ϯ 5.56 ng/L. In comparison, two healthy subjects also showed detectable IL-17A levels of 6.4 and 9.4 ng/L, respectively. Characteristics of patients related to elevated IL-17A levels are given in 
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To the Editor:
We thank Dr Harbaum and colleagues for their comments on our study in CHEST . 1 Although we compared the frequency of IL17A-producing CD4 1 T-helper (Th ) 17 cells in patients aff ected with pulmonary arterial hypertension (PAH) and healthy control (HC) subjects and investigated the mechanisms of their polarization though dendritic-and T-cell interaction, they measured the serum concentration of IL17A in HC subjects and patients with idiopathic PAH. Th e relatively low number of samples that displayed a detectable level of IL17A led them to question the relevance of the Th 17 response in PAH. However, we would suggest that it is important to realize that cytokines in the serum result from the "overfl ow" of tissue cytokines into the circulation as tissue damage increases. Hence, it does not directly mirror the circulating cell and local pulmonary responses.
We should also highlight potential technical issues in their study. Gaowa et al 2 recently analyzed the Th 17 and regulatory T-cell subsets (a T-cell lineage that counteracts proinflammatory cascades activated by Th 17 cells) in patients with connective tissue diseases (CTDs) and CTD-associated PAH (CTD-aPAH) as compared with HC subjects. Th ey found that patients with CTD-aPAH had signifi cantly higher serum IL17A than did those with CTDs or HC subjects. IL17A was detectable in all groups, with values almost 10 times higher than those from Dr Harbaum and colleagues.
Moreover, circulating Th cells do not produce cytokines "at rest" but need to be activated to start producing cytokines. Gaowa et al 2 also analyzed the IL17Aproducing T cells, as we did, after in vitro stimulation of isolated circulating T cells, to have a direct quantifi cation of Th 17 cells. Th ey found an increase in peripheral Th17 cells and in ROR g t messenger RNA levels (a transcription factor that drives the Th 17 lineage commitment). Importantly, the Th 17/regulatory T-cell subsets ratio was signifi cantly related to the severity and prognosis of CTD-aPAH. Moreover, microarray data confi rmed that gene functional groups shared by systemic sclerosis associated-PAH and idiopathic PAH lungs include IL17A signaling. 3 Importantly, IL21, which is mainly derived from Th 17 cells, plays a critical role in the pathogenesis of experimental PAH in mice, 4 and one can expect similar mechanisms in patients with PAH.
Finally, it has been shown that prostaglandin (PG) I2 (prostacyclin) signaling drives Th 17 diff erentiation by inhibiting the production of cytokines known to negatively regulate Th17 production. 5 However, we had too few patients with PAH treated with PGI2 to make a correlation between PGI2 exposure and Th17 polarization. Th is deserves further investigation, because a potential PGI2-driven Th 17 response may aggravate a potential autoimmune background in these patients.
